Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Next Previous
Trial Profile

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Safety and Tolerability of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lirentelimab (Primary)
  • Indications Eosinophilic gastroenteritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allakos

Most Recent Events

  • 30 Mar 2023 Status changed from active, no longer recruiting to completed.
  • 27 Oct 2021 Results (As of March 2021, n=25) assessing the long-term safety and efficacy of lirentelimab, an open-label extension (OLE) study, and present data by disease type (EG with or without EoD versus EoD without EG) through week 94, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
  • 27 Oct 2021 Results of an analysis compared symptom responses of patients with new diagnoses (de novo patients) with those of patients with prior diagnoses of EG and/or EoD to lirentelimab in ENIGMA and an open-label extension study.presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top